Key facts
- TriAgenics’s last known valuation is $36.0M (Sep 2025).
- It has raised $11.8M across 3 recorded rounds; the latest was Seed Round ($500K) in Apr 2025.
- Notable investors include Asclepius Ventures, Inspiros Ventures, Startup Warrior.
- TriAgenics has filed 4 Form Ds with the SEC since 2018, most recently Apr 2025 ($500K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for TriAgenics
Funding rounds
3 roundsAbout TriAgenics
Developer of medical instruments designed to block the formation of wisdom teeth. The company's instruments include a patient-specific surgical kit with disposable components along with technology that controls aspects of the third molar tooth bud ablation (3TBA) process, enabling people to have access to a lifetime of improved oral health.
- Sector
- Healthcare
- HQ
- Redmond, OR, United States
- Founded
- 2016
- Employees
- 3
- Website
- triagenics.com/
- Ownership
- Privately Held (backing)
TriAgenics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TriAgenics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TriAgenics in its N-PORT filings yet. We sweep new filings monthly.